|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.63 USD | +0.19% |
|
+7.08% | +6.11% |
| Capitalization | 461.55Cr 392.63Cr 363.91Cr 341.86Cr 636.1Cr 42TCr 674.94Cr 4.15TCr 1.65TCr 20TCr 1.73TCr 1.7TCr 73TCr | P/E ratio 2025 * |
10.5x | P/E ratio 2026 * | 18.6x |
|---|---|---|---|---|---|
| Enterprise value | 430.12Cr 365.9Cr 339.13Cr 318.59Cr 592.8Cr 39TCr 628.99Cr 3.87TCr 1.54TCr 19TCr 1.61TCr 1.58TCr 68TCr | EV / Sales 2025 * |
6.96x | EV / Sales 2026 * | 4.51x |
| Free-Float |
90.42% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: TG Therapeutics, Inc.
| 1 day | +0.19% | ||
| 1 week | +7.08% | ||
| Current month | +6.11% | ||
| 1 month | +2.10% | ||
| 3 months | -10.19% | ||
| 6 months | -15.47% | ||
| Current year | +6.11% |
| 1 week | 29.8 |  | 31.97 |
| 1 month | 26.89 | | 33.24 |
| Current year | 26.89 | | 33.24 |
| 1 year | 25.28 | | 46.48 |
| 3 years | 6.46 | | 46.48 |
| 5 years | 3.48 | | 56.5 |
| 10 years | 3.32 | | 56.74 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 60 | 29/12/2011 |
Sean Power
DFI | Director of Finance/CFO | 44 | 29/12/2011 |
Jenna A. Bosco
IRC | Investor Relations Contact | - | 01/12/2011 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CHM | Chairman | 60 | 29/12/2011 |
Laurence Charney
BRD | Director/Board Member | 79 | 01/03/2012 |
Yann Echelard
BRD | Director/Board Member | 62 | 09/11/2012 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.19% | +7.08% | +5.93% | +156.32% | 461.55Cr | |
| +0.82% | +1.31% | +46.48% | +214.21% | 97TCr | |
| +0.22% | -0.03% | +47.48% | +29.48% | 53TCr | |
| +0.91% | -1.70% | +26.36% | +45.81% | 38TCr | |
| +0.93% | +1.10% | +28.76% | +18.21% | 37TCr | |
| +1.66% | -5.48% | +22.69% | +21.07% | 28TCr | |
| +0.66% | -0.83% | +28.80% | +36.25% | 28TCr | |
| -1.74% | -1.65% | +13.45% | -0.69% | 28TCr | |
| +6.11% | +4.88% | -30.84% | -17.87% | 26TCr | |
| +1.01% | +5.50% | +26.29% | +31.85% | 19TCr | |
| Average | +1.21% | -0.04% | +21.54% | +53.46% | 35.24TCr | |
| Weighted average by Cap. | +0.96% | -0.67% | +29.91% | +74.99% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 62Cr 53Cr 49Cr 46Cr 85Cr 5.65TCr 90Cr 555.62Cr 220.55Cr 2.67TCr 231.58Cr 226.83Cr 9.78TCr | 89Cr 76Cr 70Cr 66Cr 122.65Cr 8.15TCr 130.14Cr 800.69Cr 317.82Cr 3.85TCr 333.72Cr 326.87Cr 14TCr |
| Net income | 49Cr 41Cr 38Cr 36Cr 67Cr 4.44TCr 71Cr 436.87Cr 173.41Cr 2.1TCr 182.08Cr 178.35Cr 7.69TCr | 28Cr 24Cr 22Cr 21Cr 39Cr 2.59TCr 41Cr 254.52Cr 101.03Cr 1.23TCr 106.08Cr 103.91Cr 4.48TCr |
| Net Debt | -31Cr -27Cr -25Cr -23Cr -43Cr -2.88TCr -46Cr -282.71Cr -112.22Cr -1.36TCr -117.83Cr -115.41Cr -4.98TCr | -61Cr -52Cr -48Cr -45Cr -84Cr -5.55TCr -89Cr -545.38Cr -216.48Cr -2.63TCr -227.31Cr -222.64Cr -9.6TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/26/22 | 31.63 $ | +0.19% | 16,09,373 |
| 21/26/21 | 31.57 $ | +2.04% | 15,89,176 |
| 20/26/20 | 30.94 $ | +1.21% | 23,62,574 |
| 16/26/16 | 30.57 $ | -0.46% | 24,99,003 |
| 15/26/15 | 30.71 $ | +3.96% | 39,74,815 |
Delayed Quote Nasdaq, January 23, 2026 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TGTX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition